Adaptive and Genentech join forces to develop shared and personalized T cell–based therapies for cancer patients, validating the therapeutic potential of Adaptive’s platform.
Years: 2019
Adaptive Goes Public
In one of the biggest biotech IPOs of the year, Harlan and Chad Robins ring the Nasdaq opening bell as Adaptive is listed under the ticker symbol ADPT.
clonoSEQ Covered by Medicare
Patients with certain blood cancers are ensured access by Medicare for MRD assessment to support more personalized treatment decisions. This paves the way for further coverage by private payers.